+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 29 Actively Recruiting clinical trials

P

Actively Recruiting

Healthy Volunteer

Researchers are conducting a prospective study to evaluate the survival and clinical outcomes of hip implants, specifically the Trident II cup, in patients undergoing total hip replacement. The study aims to follow a group of at least 500 patients from several high-volume centers in Sweden to assess implant performance and patient health over time. The focus is on comparing two types of non-cemented Trident II acetabular cups and determining if there is any evidence of inferiority according to orthopedic benchmarking standards. Participants will receive total hip arthroplasty using either the Trident II Hemispherical cup or the Trident II Tritanium cup. Clinical data such as the EQ-5D, Oxford Hip Score, and Forgotten Joint Score will be collected before surgery and at 1, 3, 6, and 10 years afterwards. Imaging assessments including conventional X-rays will be performed before surgery, immediately after, and at 3, 6, and 10 years post-operation. Additionally, a subgroup of patients will undergo detailed implant migration analysis using Computer Tomography Microanalysis CTMA at postoperative, 3 months, 6 months, and 2 years. Throughout the study, participants will undergo regular evaluations involving clinical questionnaires, X-rays, and CT scans for those in the sub-cohort. The main outcome measured is implant survival at 3 years, with additional monitoring extending to 10 years for survival, quality of life scores, radiographic findings, and adverse events from national and regional patient registries. The total participation period can last up to 10 years, with multiple follow-up visits planned to closely monitor implant performance and patient well-being.

Age: 30Years - 75YearsAll GendersPhase Not Applicable
1 location
C

Actively Recruiting

Researchers are evaluating how well a new injectable medicine called cagrilintide helps adults with excess body weight to lose weight. This phase 3 trial compares two different presentations of cagrilintide to placebo in people with overweight or obesity. The purpose is to understand the relative change in body weight from the start of treatment to the end of 26 weeks of treatment. Participants will be randomly assigned to one of three groups receiving weekly subcutaneous injections for 26 weeks one group receives cagrilintide with placebo matched to semaglutide in one device and placebo matched to cagrilintide in another another group receives cagrilintide in one device with matched placebos in the other and the last group receives matched placebos in both devices. This double-blind study uses devices for administration and treatment allocation is random. During the study, participants will have regular assessments including measurements of body weight and monitoring for adverse events from the start through 33 weeks. The main outcome measured is the relative change in body weight after 26 weeks of treatment. Safety is also monitored by counting any treatment-emergent adverse events or serious adverse events. Participants are involved for about 9 months in total.

Age: 18Years +All GendersPhase 3
36 locations
P

Actively Recruiting

Healthy Volunteer

Researchers are studying the effects of eloralintide compared to a placebo on insulin sensitivity, metabolic health, and body weight in adults who are overweight or have obesity. This phase 1 study focuses on understanding how these treatments influence how the body responds to insulin and other metabolic factors. Participants in this study are adults aged 18 to 70 years with a body mass index between 25 and 45 kgm, and without diabetes. Participants will be randomly assigned to receive either eloralintide or a placebo, both administered by subcutaneous injection. The study lasts about 35 weeks and includes 3 inpatient visits totaling 7 days. The design is double-blind, so neither the participants nor the researchers know who receives the active drug or placebo during the trial. During the study, participants will undergo assessments to measure changes in insulin sensitivity using a hyperinsulinemic euglycemic clamp test at baseline and week 24. Body weight changes will also be tracked over the same period. Participants must maintain lifestyle and dietary guidelines throughout the study. The research team will monitor safety and overall health during the visits and follow the participants until study completion around 2027.

Age: 18Years - 70YearsAll GendersPhase 1
2 locations
C

Actively Recruiting

Researchers are evaluating how well guselkumab works compared to risankizumab in people with moderately to severely active Crohns Disease, a long-term condition causing severe inflammation in the intestines. This Phase 3b study aims to compare the effectiveness and safety of these two treatments to better understand their impact on this condition. Participants will receive either guselkumab or risankizumab following specific dosing schedules. Those receiving guselkumab will get induction doses by subcutaneous injection at Weeks 0, 4, and 8, then maintenance doses every 4 weeks from Week 12 through Week 52. Participants in the risankizumab group will receive induction doses intravenously at Weeks 0, 4, and 8, followed by maintenance doses by subcutaneous injection every 8 weeks from Week 12 to Week 52. During the study, participants will be monitored for deep remission at Week 52, along with other outcomes like clinical remission, endoscopic response, and steroid-free remission. Safety will be assessed by tracking adverse events and lab test abnormalities up to Week 165. Follow-up will continue to evaluate long-term effects, with participant involvement lasting until study completion in 2030.

Age: 18Years +All GendersPhase 3
164 locations
E

Actively Recruiting

Researchers are evaluating the effects of AZD6234 as an additional treatment alongside incretin-based therapies in adults who are overweight or have obesity with at least one weight-related health condition, with or without Type 2 Diabetes Mellitus. This Phase III global study will compare how well AZD6234 works against a placebo by measuring changes in body weight over 68 weeks. Participants will be randomly assigned to receive either AZD6234 or a matching placebo, both given as weekly injections under the skin. These treatments will be added to their stable dose of existing incretin-based medications. The study is designed to monitor participants for 68 weeks of treatment to assess the impact on body weight and related health measures. During the study, participants will undergo regular assessments including body weight measurements, waist circumference, blood pressure, blood tests for triglycerides and HbA1c, and evaluation of weight loss milestones. Safety and effectiveness will be closely monitored throughout the treatment period, which lasts about 68 weeks. The study aims to provide detailed information on how AZD6234 affects weight and metabolic health in this population.

Age: 18Years +All GendersPhase 3
96 locations
E

Actively Recruiting

Alopecia areata AA is a condition where the immune system attacks hair follicles, causing hair loss typically on the head and face but potentially on any body part. This research aims to evaluate the safety, effectiveness, and tolerability of upadacitinib tablets in adolescents and adults with severe AA. The study involves multiple phases to assess different doses of upadacitinib compared to placebo. Participants are randomly assigned to one of three treatment groups receiving either upadacitinib Dose A, Dose B, or placebo tablets daily. Those on placebo may be re-randomized to upadacitinib groups depending on their Severity of Alopecia Tool SALT score at Week 24. The study includes periods A and B lasting up to 52 weeks each, with some participants continuing treatment for up to 108 weeks in an extension phase. The trial enrolls about 1500 participants worldwide. During the study, participants take oral tablets daily and attend regular visits at clinics or hospitals. Their response to treatment is monitored through medical assessments, blood tests, questionnaires, and side effect checks. The main outcomes measured include changes in SALT scores and recording adverse events over approximately 164 weeks. Follow-up occurs for up to 30 days after the last dose to monitor safety and treatment effects.

Age: 12Years - 63YearsAll GendersPhase 3
272 locations
E

Actively Recruiting

Healthy Volunteer

Researchers are evaluating the safety and performance of a dermal filler called DKL crosslinked hyaluronic acid 20 mgmL with lidocaine 0.3% for lip augmentation in healthy men and women who have thin lips and desire fuller lips. This single-arm, open-label study involves participants acting as their own control to assess the improvement in lip appearance over time. Participants will receive injections of the DKL crosslinked sodium hyaluronate 20 mgmL with lidocaine 0.3% dermal filler into both their upper and lower lips. The study focuses on lip augmentation using this injectable sterile gel. The treatments effect will be evaluated at multiple time points up to 48 weeks after the initial injection. Assessments include pain during injection, aesthetic improvements, and device usability. During the study, participants will undergo evaluations of lip fullness using the Lip Fullness Grading Scale and aesthetic improvements rated by both investigators and subjects. Other assessments include lip function, sensation, texture, and satisfaction with the lips and overall outcome. Participants will keep diaries to track post-treatment events and adverse effects. The study lasts up to 48 weeks, with multiple follow-up visits to monitor safety and effectiveness of the filler.

Age: 18Years +All GendersPhase Not Applicable
2 locations
E

Actively Recruiting

Researchers are evaluating the cardiovascular outcomes of elecoglipron compared with a placebo in adults with heart failure with preserved ejection fraction HFpEF or mildly reduced ejection fraction HFmrEF. This Phase III, randomized, double-blind, placebo-controlled study includes participants regardless of type 2 diabetes status who are also taking dapagliflozin along with other standard care treatments. Participants are randomly assigned to receive either elecoglipron tablets once daily or matching placebo tablets once daily. The study is conducted across multiple centers and follows a parallel-group design. The treatment period may last up to 42 months, during which the effects of elecoglipron on cardiovascular events and patient outcomes are assessed. Throughout the study, participants undergo regular evaluations to monitor their heart failure status, including assessments of cardiovascular death risk, hospitalization for heart failure, and urgent heart failure visits. Patient-reported outcomes are collected using questionnaires at baseline and at 52 weeks. Safety and efficacy are closely monitored over the extended treatment period to determine the impact of elecoglipron compared to placebo.

Age: 18Years +All GendersPhase 3
679 locations
S

Actively Recruiting

Residual limping due to gluteus medius insufficiency after total hip replacement is a serious complication without effective treatment. This study aims to compare surgical reconstruction of the gluteus medius using an Achilles tendon allograft with non-surgical physiotherapy treatment. The hypothesis is that surgery followed by physiotherapy will improve hip function and reduce limping more than physiotherapy alone. Participants are randomly assigned to one of two groups. One group undergoes surgical reconstruction where an Achilles tendon allograft with a calcaneus block is fixed to the greater trochanter and tensioned through the gluteus medius muscle, followed by partial weight bearing for 2 months and 10 months of physiotherapy. The other group receives only physiotherapy for 12 months without surgery. Throughout the study, participants will be assessed at 12 months using the Oxford Hip Score to measure hip function. Additional evaluations include Trendelenburgs sign, hip abduction strength, activity levels, quality of life indexes, and monitoring of any adverse events. The total study duration for each participant is 12 months, with close observation of treatment outcomes and safety.

Age: 40Years - 80YearsAll GendersPhase Not Applicable
1 location
E

Actively Recruiting

This research aims to explore how bacteria and fungi from hard-to-heal wounds bind to special wound dressings coated with dialkylcarbamoyl chloride DACC. It focuses on patients with wounds that have not healed well, such as diabetic foot ulcers, venous leg ulcers, pressure ulcers, and arterial leg ulcers. The study is an open, exploratory clinical investigation conducted at a single center, designed to gain insights into the interaction between microbes and three types of Sorbact dressings. Participants will be assigned to one of three groups based on the type of Sorbact dressing deemed most suitable for their wounds Sorbact Compress, Sorbact Gel Dressing, or Sorbact Ribbon Gauze. Each dressing uses the same technology to bind bacteria and fungi, and the study will evaluate each device separately without comparing them directly. The treatment period will last 14 days, and dressings will be used following the manufacturers instructions for use. During the study, participants will have three clinic visits a screening and baseline visit, followed by two additional visits during the treatment period. Researchers will assess the microbial species bound to the dressings after about two days, as well as the wound microbial load, species present, and inflammatory markers in wound fluid at baseline and after 14 days. There is no additional follow-up after the treatment period. This helps researchers understand how these dressings interact with microbes in hard-to-heal wounds.

Age: 18Years +All GendersPhase Not Applicable
1 location

1-10 of 29

1